Company Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S.
aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N.
gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Country | Denmark |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Christian Kanstrup |
Contact Details
Address: Dr. Neergaards Vej, 5th Floor Horsholm, 2970 Denmark | |
| Phone | 45 31 31 97 53 |
| Website | evaxion.ai |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R105 |
| ISIN Number | US29970R2040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Kanstrup M.Sc. | Chief Executive Officer |
| Andreas Holm Mattsson | Founder and Chief AI Officer |
| Thomas Frederik Schmidt | Chief Financial Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 27, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | 424B5 | Filing |
| Mar 25, 2025 | 6-K | Report of foreign issuer |
| Mar 24, 2025 | EFFECT | Notice of Effectiveness |
| Mar 13, 2025 | F-3 | Filing |
| Mar 4, 2025 | 6-K | Report of foreign issuer |
| Feb 25, 2025 | 6-K | Report of foreign issuer |